Search
Ephedra sinica root
go.drugbank.com/drugs/DB01363ApprovedNutraceuticalThe drug is still sold in Canada in OTC formulations for respiratory conditions associated with bronchial asthma. … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for
Products: Fyto-HB I- Cap 10mgTriprolidine
go.drugbank.com/drugs/DB00427ApprovedFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSDiethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalA appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. … It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
International brands: LineaAbametapir
go.drugbank.com/drugs/DB11932Approved[A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigationalIt works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]
Donanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigationalDonanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.
Pyrethrum extract
go.drugbank.com/drugs/DB11087ApprovedThe active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans. … Pyrethrum extract is also used used to treat head, body, and pubic lice infections.
Categories: Compounds used in a research, industrial, or household settingEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalMutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion. … [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243] … Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists.